Inclusion Criteria: * Willing and able to give consent/assent * Clinical diagnosis of epidermolysis bullosa * Confirmation of diagnosis (either DDEB or RDEB) by genetic testing including COL7A1. * Age: 2 months of age and older at the time of informed consent/assent * Women of childbearing age must be willing to use reliable birth control method throughout the treatment duration and for 3 months following the last treatment application Exclusion Criteria: * Diseases or conditions that could interfere with the assessment of safety of the study treatment and compliance of the participant with study visits/procedures, as determined by the Investigator * Pregnant or nursing women * Active infection in the area that will undergo administration, that the Investigator believes will negatively impact the IP application * Known allergy to any of the constituents of the product * Concurrent skin transplant or mesh skin grafting; if the participant is currently having transplantation or grafting surgeries they must wait until the transplant has begun to heal and the graft has absorbed prior to initiating B-VEC therapy * Participation in an interventional gene therapy clinical trial within the past three (3) months (not including B-VEC administration)